Donanemab

Product

Anti-amyloid antibody for Alzheimer's disease developed by Eli Lilly, marketed as Kisunla

3 stories

Experimental Drug Shows First-Ever Reduction in Tau Pathology and Cognitive Benefit in Early Alzheimer's Trial

Study Concludes Anti-Amyloid Alzheimer's Drugs Have No Clinically Meaningful Effect

Researchers Identify 'Death Switch' Mechanism in Alzheimer's Disease